Organization (Industry)
Tanabe Pharma Corporation (Japan)
ClinicalTrials.gov lists Tanabe Pharma Corporation (Japan) as lead sponsor of 133 trials. It has 192 active development programs and 27 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo 三菱ケミカル株式会社, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Tanabe Pharma Corporation (Japan): 133 lead-sponsored trials and 2 legal-entity registrations. The parent company on record for Tanabe Pharma Corporation (Japan) is Mitsubishi Group (Japan), which does not have its own page on this site.
Disease areas (73)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 31 |
| Diabetes Mellitus, Type 2 | 24 |
| Renal Insufficiency, Chronic | 13 |
| Hepatitis C | 12 |
| Insulin Resistance | 11 |
Showing 5 of 73 disease areas.
Trials by start year as sponsor or collaborator (25)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 2 |
| 2019 | 1 |
| 2018 | 7 |
| 2017 | 7 |
| 2016 | 10 |
Showing 10 of 25 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (192)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| GOBIK Aqueous Suspension Syringes | Haemophilus Infections | Phase 3 | 1 |
| GOBIK Aqueous Suspension Syringes | Hepatitis B | Phase 3 | 1 |
| GOBIK Aqueous Suspension Syringes | Clostridium Infections | Phase 3 | 1 |
| GOBIK Aqueous Suspension Syringes | Diphtheria | Phase 3 | 1 |
| GOBIK Aqueous Suspension Syringes | Poliomyelitis | Phase 3 | 1 |
Showing 5 of 192 active programs.
Approved assets (27)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Canagliflozin | 7 |
| Argatroban | 3 |
| INSULIN GLARGINE | 3 |
| Alteplase | 2 |
| Teneli (Teneligliptin) | 1 |
Showing 5 of 27 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 91% hit target (n=23) | 68% on time (n=22) |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 4 | 2026-08-19 |
Biomarker capability evidence (151)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 151 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Counted at group level under Mitsubishi Chemical (Japan): journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.